Equities

BRAIN Biotech AG

BRAIN Biotech AG

Actions
Basic MaterialsChemicals
  • Price (EUR)2.83
  • Today's Change0.08 / 2.91%
  • Shares traded1.08k
  • 1 Year change-53.76%
  • Beta1.1913
Data delayed at least 15 minutes, as of Apr 26 2024 08:57 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

BRAIN Biotech AG, formerly known as BRAIN Biotechnology Research and Information Network AG is a Germany-based industrial biotechnology company develops and brings to market biological ingredients for Nutrition & Health, SkinCare and Industrial BioSolutions. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.

  • Revenue in EUR (TTM)55.23m
  • Net income in EUR-8.40m
  • Incorporated2000
  • Employees311.00
  • Location
    BRAIN Biotech AGDarmstaedter Strasse 34-36ZWINGENBERG 64673GermanyDEU
  • Phone+49 625193310
  • Fax+49 6 251933111
  • Websitehttps://www.brain-biotech.de/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
BNNX.N:GER since
announced
Transaction
value
Biocatalysts LtdAnnounced24 May 202324 May 2023Announced-44.07%--
Data delayed at least 15 minutes, as of Apr 26 2024 08:57 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
NanoRepro AG13.93m-6.58m23.87m17.00--0.5568--1.71-0.5328-0.53281.143.320.28641.441.53733,372.60-13.5220.52-13.9223.1532.4635.59-47.2211.8342.54--0.0031.99-76.3587.53-112.53--56.67--
B.M.P. Pharma Trading AG1.64k1.57m32.98m45.0021.07--21.0120,107.490.2990.2990.0003--------36.44--16.68--17.58-46.340.234795,712.2087,097.18---493.86-----96.34-61.6075.3943.01----
MediGene AG-100.00bn-100.00bn47.01m86.00--1.96----------0.8144-----------22.31---25.28--90.15---123.17----0.1228---80.69-4.89-94.20---8.12--
BRAIN Biotech AG55.23m-8.40m60.08m311.00--2.93--1.09-0.3843-0.38432.530.93750.7778----167,351.50-11.67-10.71-15.18-14.4656.1256.16-15.01-17.47---2.800.00--11.7914.12-25.63--14.47--
Apontis Pharma AG36.96m-11.30m70.72m177.00--2.29--1.91-1.32-1.324.373.630.63023.0923.11208,835.00-19.27---22.64--62.68---30.58--2.58--0.1659---33.67---520.38------
4Sc AG304.00k-8.24m89.54m15.00--17.78--294.55-0.8144-0.81440.03010.49950.0236--3.6820,266.67-63.84-39.49-77.78-42.8468.7592.24-2,709.54-337.74----0.00---30.28-40.7842.64---56.05--
Haemato AG260.81m9.61m89.68m78.009.340.59998.330.34381.841.8450.1028.671.479.8012.483,343,690.005.412.016.452.707.568.423.681.211.66--0.0203157.20-12.95-3.0325.393.32-5.75-16.74
Cantourage Group SE-100.00bn-100.00bn97.97m2.00--2.21----------3.72----------------------------0.00--------------
Heidelberg Pharma AG9.05m-18.28m141.21m98.00--3.13--15.60-0.3957-0.39570.1960.9680.12220.218711.8795,273.69-24.68-43.91-33.18-64.3479.7552.13-201.94-206.242.22--0.104---46.7521.87-3.27---0.8341--
PharmaSGP Holding SE97.55m14.99m266.40m85.0017.787.2810.932.731.251.258.133.050.75921.159.691,234,848.0011.6714.6213.9821.2290.6189.9015.3719.172.159.030.6809--31.3410.0911.820.288614.67--
Data as of Apr 26 2024. Currency figures normalised to BRAIN Biotech AG's reporting currency: Euro EUR
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.